Arctic Bioscience — Report Publication Announcement 2023

Aug 22, 2023

Arctic Bioscience - Invitation to presentation of half year 2023 results

Arctic Bioscience - Invitation to presentation of half year 2023 results

Arctic Bioscience will publish its financial results for the half year 2023 on

Tuesday 29[th] of August, at 08:00 CET.

The same day at 12:00 CET, the Company will host a webcast to present the

results and give an operational update. Following the presentation, it will be

opened for questions from the audience.

Webcast details:

Date: Tuesday 29[th] of August 2023

Time: 12:00 CET

Format: Webcast and Q&A

Language: English

The presentation can be accessed through the Company's website, or with the link

below:

Link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230829_3

Participants will be required to register to view the webcast and participate in

the Q&A.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel investigational drug candidate.

HRO350 is being developed for treatment of patients with mild-to-moderate

psoriasis. This is a large patient group in need of new effective medicines with

beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.